Edwards Lifesciences CFO granted new equity awards

Mistras Theodora reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Mistras Theodora reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences Corp reported that its CVP, Chief Financial Officer Theodora Mistras received multiple equity awards on July 9, 2026 under the company’s Long-Term Stock Incentive Compensation Program. The awards include restricted stock units, performance-based restricted stock units, and employee stock options with multi‑year vesting schedules tied to continued service and, for the performance units, achievement of specified performance goals.

Insights

Equity Compensation Analyst

CFO received routine multi-year equity awards aligning pay with performance.

Theodora Mistras, CVP and Chief Financial Officer of Edwards Lifesciences, received grants of restricted stock units, performance rights, and stock options under the company’s long-term incentive program on July 9, 2026. These awards are structured with multi-year vesting and, for some units, performance conditions.

The filing lists $0.00 grant prices for the shares and options, confirming these are compensation awards rather than open-market purchases. The stock options cover 61,800 shares at an exercise price of $91.33 per share, becoming exercisable in four equal annual installments starting one year after grant. Performance-based units scheduled to vest on July 9, 2029 can pay out between 0% and 200% of the target number depending on three-year performance.

Because these are standard incentive grants with no sales or dispositions, the economic signal is neutral. For investors, this mainly confirms that the CFO’s compensation includes a significant long-term equity component, tying a portion of her potential rewards to both share price and performance over several years.

Insider Trade Summary

Grant/Award: 174,045 shares

Grant/Award 4 txns

Insider Mistras Theodora

Role CVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Acquire) F3	61,800	$0.00	$0.00
Grant/Award	Performance Rights F4	12,325	$0.00	$0.00
Grant/Award	Common Stock F1	87,595	$0.00	$0.00
Grant/Award	Common Stock F2	12,325	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 61,800 contracts (Direct); Performance Rights — 12,325 contracts (Direct); Common Stock — 99,920 shares (Direct)

Footnotes (4)

1. F1. These restricted stock units were granted on July 9, 2026, under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest as follows: 43.75% on the first anniversary of May 29, 2026 (the "Start Date"), 50% on the second anniversary of the Start Date, and the remaining 6.25% on the third anniversary of the Start Date.
2. F2. These restricted stock units were granted on July 9, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
3. F3. These options were granted on July 9, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
4. F4. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on July 9, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.

Key Figures

Restricted stock units grant: 12,325 shares Additional restricted stock units grant: 87,595 shares Performance rights target award: 12,325 shares +3 more

6 metrics

Restricted stock units grant 12,325 shares Restricted stock units granted on July 9, 2026 under the Long-Term Stock Incentive Compensation Program

Additional restricted stock units grant 87,595 shares Restricted stock units in Edwards Lifesciences common stock granted on July 9, 2026

Performance rights target award 12,325 shares Target number of shares for performance-based restricted stock units scheduled to vest on July 9, 2029

Stock options granted 61,800 options Employee stock options granted on July 9, 2026 under the Long-Term Stock Incentive Compensation Program

Option exercise price $91.33 per share Conversion or exercise price for 61,800 employee stock options

Performance vesting range 0% to 200% of Target Awards Range of potential vesting for performance-based restricted stock units over a three-year performance period

Key Terms

restricted stock units, Performance Rights, Long-Term Stock Incentive Compensation Program, Target Award

4 terms

restricted stock units financial

"These restricted stock units were granted on July 9, 2026, under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Performance Rights financial

"Security title: Performance Rights with underlying Edwards Lifesciences common stock"

Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.

Long-Term Stock Incentive Compensation Program financial

"granted on July 9, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"

Target Award financial

"Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026"

FAQ

What equity awards did Edwards Lifesciences (EW) grant to CFO Theodora Mistras?

Edwards Lifesciences granted CFO Theodora Mistras restricted stock units, performance rights, and employee stock options on July 9, 2026 under its Long-Term Stock Incentive Compensation Program, all subject to multi-year vesting schedules.

How many employee stock options did the Edwards Lifesciences (EW) CFO receive and at what exercise price?

The CFO received 61,800 employee stock options, each with an exercise price of $91.33 per share. These options are scheduled to become vested and exercisable in four equal annual installments beginning one year after the grant date.

What are the vesting terms for the restricted stock units reported by Edwards Lifesciences (EW)?

Certain restricted stock units granted on July 9, 2026 vest in four equal annual installments starting one year after grant. Another grant vests 43.75%, then 50%, then 6.25% on successive anniversaries of a defined Start Date.

How do the performance-based restricted stock units for Edwards Lifesciences (EW) CFO work?

Performance-based restricted stock units cover a target of 12,325 shares scheduled to vest on July 9, 2029. The actual number vesting will range from 0% to 200% of the target based on three-year performance goals.

Did the Edwards Lifesciences (EW) CFO buy or sell any shares in the latest Form 4?

No open-market buys or sells were reported. All transactions were coded as grant or award acquisitions, reflecting stock, performance rights, and option awards granted as compensation, each at a grant price of $0.00.

Are the new Edwards Lifesciences (EW) equity awards to the CFO immediately exercisable or vested?

No, they vest over time. The options and some restricted stock units begin vesting one year after grant in four equal annual installments, while certain performance-based units vest in full on July 9, 2029 if performance goals are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 05:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mistras Theodora

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		A		87,595(1)	A	$0.0000	87,595	D
Common Stock	07/09/2026		A		12,325(2)	A	$0.0000	99,920	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$91.33	07/09/2026		A		61,800		07/09/2027(3)	07/08/2033	Common Stock	61,800	$0.0000	61,800	D
Performance Rights	(4)	07/09/2026		A		12,325		07/09/2029	(4)	Common Stock	12,325	$0.0000	12,325	D

Explanation of Responses:

1. These restricted stock units were granted on July 9, 2026, under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest as follows: 43.75% on the first anniversary of May 29, 2026 (the "Start Date"), 50% on the second anniversary of the Start Date, and the remaining 6.25% on the third anniversary of the Start Date.

2. These restricted stock units were granted on July 9, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

3. These options were granted on July 9, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

4. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on July 9, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)